Markets:

Overview

News

Currencies

International

Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

19.70 +1.13 (+6.06%)

Streaming Delayed Price Updated: 3:53 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19

December 01, 2021

From Fulgent Genetics, Inc.

Via Business Wire

56 Biggest Movers From Friday ↗

November 29, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on...

Via Benzinga

Is Fulgent Genetics Undervalued? ↗

November 28, 2021

Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.

Via The Motley Fool

48 Stocks Moving In Friday's Mid-Day Session ↗

November 26, 2021

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...

Via Benzinga

3 Small-Cap COVID Stocks With Huge Upside ↗

November 25, 2021

Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics.

Via The Motley Fool

The Monster Business Lurking Behind Fulgent's COVID Results ↗

November 24, 2021

Fulgent's recent earnings report confirmed the strength of its core testing business.

Via The Motley Fool

A Look Into Healthcare Sector Value Stocks ↗

November 22, 2021

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

How Is Fulgent Genetics Staying Ahead of Its Competition? ↗

November 20, 2021

The key is by focusing on doctors.

Via The Motley Fool

What Investors Should Like About Fulgent Genetics' Q3 Results ↗

November 19, 2021

The genetic testing company delivered a solid performance in Q3.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 10, 2021

Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6...

Via Benzinga

Fulgent Genetics Q3 Revenues More Than Double; Raises FY21 Outlook ↗

November 10, 2021

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19...

Via Benzinga

Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

FLGT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Fulgent Genetics: Q3 Earnings Insights ↗

November 09, 2021

Fulgent Genetics (NASDAQ:FLGT) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Fulgent Genetics Reports Third Quarter Financial Results

November 09, 2021

From Fulgent Genetics, Inc.

Via Business Wire

Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences

November 09, 2021

From Fulgent Genetics, Inc.

Via Business Wire

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19

October 27, 2021

From Fulgent Genetics, Inc.

Via Business Wire

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street ↗

October 27, 2021

The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.

Via The Motley Fool

Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021

October 25, 2021

From Fulgent Genetics, Inc.

Via Business Wire

Fulgent Genetics Stock Meets 80-Plus Relative Strength Rating Benchmark ↗

October 11, 2021

A Relative Strength Rating upgrade for Fulgent Genetics shows improving technical performance.

Via Investor's Business Daily

What's Going on With Fulgent Genetics? ↗

October 10, 2021

The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world.

Via The Motley Fool

Can This Stock Grow Despite a COVID Testing Decline? ↗

October 05, 2021

Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.

Via The Motley Fool

These 3 Top Healthcare Stocks Are Screaming Buys Right Now ↗

September 29, 2021

If the market crashes these companies could be insulated.

Via The Motley Fool

Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program

September 23, 2021

From Fulgent Genetics, Inc.

Via Business Wire

3 Unstoppable Healthcare Stocks to Buy With Just $1,000 ↗

September 22, 2021

It doesn't take much when you buy great companies and let them grow.

Via The Motley Fool

The 1 Stock I'd Buy Right Now ↗

September 18, 2021

The pandemic isn't over yet.

Via The Motley Fool

Fulgent Genetics's Return on Invested Capital Overview ↗

September 14, 2021

Pulled from Benzinga Pro data, Fulgent Genetics (NASDAQ:FLGT) posted Q2 earnings of $98.90 million, an increase from Q1 of 62.95%. Sales dropped to $153.62 million, a 57.26%...

Via Benzinga

10 Million Reasons I'm Not Selling Fulgent Genetics ↗

September 02, 2021

The company is about to shock Wall Street.

Via The Motley Fool

Have $500? 3 Absurdly Cheap Healthcare Stocks Long-Term Investors Should Consider Buying Right Now ↗

August 24, 2021

Everyone loves a discount.

Via The Motley Fool

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

All News about Fulgent Genetics, Inc. - Common Stock

Starting at /week.